摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one | 487578-88-1

中文名称
——
中文别名
——
英文名称
(6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one
英文别名
(6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-1-hydroxy-6,6-dimethyl-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one
(6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one化学式
CAS
487578-88-1
化学式
C24H34O3S2
mdl
——
分子量
434.664
InChiKey
OUPICNWXPVNWII-RTBURBONSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    97.1
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    (6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 反应 1.5h, 以85%的产率得到(6aR,9R,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol
    参考文献:
    名称:
    Novel 1′,1′-Chain Substituted Hexahydrocannabinols: 9β-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist
    摘要:
    In pursuit of a more detailed understanding of the structural requirements for the key side chain cannabinoid pharmacophore, we have extended our SA R to cover a variety of conformationally modified side chains within the 9-keto and 9-hydroxyl tricyclic structures. OF the compounds described here. those with a seven-atom long side chain substituted with a cyclopentyl ring at Cl' position have very high affinities For both CB1 and CB2 (0.97 nM < K-1 < 5.25 nM), with no preference for either of the two receptors. However, presence of the smaller cyclobutyl group at the Cl' position leads to an optimal affinity and selectivity interaction with CB1. Thus, two of the Cl'-cyclobutyl analogues, namely. (6a R.10aR R)-3-(1-hexyl-cyclobut-1-y1)-6,6a,7,8, 10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo-[b,d]pyran-9-one and (6aR,9R, 10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10, 10a-hexahydro-6.6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol (7e-beta, AM2389), exhibited remarkably high affinities (0.84 and 0.16 nM respectively) and significant selectivities (16- and 26-fold, respectively) for CB1. Compound 7e-beta was found to exhibit exceptionally high in vitro and in vivo potency with a relatively long duration of action.
    DOI:
    10.1021/jm100641g
  • 作为产物:
    描述:
    (4R)-4-[4-(2-hexyl-1,3-dithiolan-2-yl)-2,6-dihydroxy-phenyl]-6,6-dimethyl-2-norpinanone三氟甲磺酸三甲基硅酯 作用下, 以 硝基甲烷二氯甲烷 为溶剂, 反应 3.0h, 以67%的产率得到(6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one
    参考文献:
    名称:
    Novel 1′,1′-Chain Substituted Hexahydrocannabinols: 9β-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist
    摘要:
    In pursuit of a more detailed understanding of the structural requirements for the key side chain cannabinoid pharmacophore, we have extended our SA R to cover a variety of conformationally modified side chains within the 9-keto and 9-hydroxyl tricyclic structures. OF the compounds described here. those with a seven-atom long side chain substituted with a cyclopentyl ring at Cl' position have very high affinities For both CB1 and CB2 (0.97 nM < K-1 < 5.25 nM), with no preference for either of the two receptors. However, presence of the smaller cyclobutyl group at the Cl' position leads to an optimal affinity and selectivity interaction with CB1. Thus, two of the Cl'-cyclobutyl analogues, namely. (6a R.10aR R)-3-(1-hexyl-cyclobut-1-y1)-6,6a,7,8, 10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo-[b,d]pyran-9-one and (6aR,9R, 10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10, 10a-hexahydro-6.6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol (7e-beta, AM2389), exhibited remarkably high affinities (0.84 and 0.16 nM respectively) and significant selectivities (16- and 26-fold, respectively) for CB1. Compound 7e-beta was found to exhibit exceptionally high in vitro and in vivo potency with a relatively long duration of action.
    DOI:
    10.1021/jm100641g
点击查看最新优质反应信息

文献信息

  • Novel bicyclic and tricyclic cannabinoids
    申请人:——
    公开号:US20040236116A1
    公开(公告)日:2004-11-25
    Novel bicyclic-cannabinoids and hexahydrocannabinol analogs are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response useful to treat a number of physiological conditions.
    本发明提供了新型双环大麻素和六氢大麻酚类似物。当以治疗有效量给个体或动物施用这些化合物时,会导致个体或动物体内该化合物的平足够高,从而引起生理反应。这种生理反应对于治疗多种生理状况非常有用。
  • NOVEL BICYCLIC AND TRICYCLIC CANNABINOIDS
    申请人:The University of Connecticut
    公开号:EP1414775A2
    公开(公告)日:2004-05-06
  • EP1414775A4
    申请人:——
    公开号:EP1414775A4
    公开(公告)日:2005-06-29
  • US7057076B2
    申请人:——
    公开号:US7057076B2
    公开(公告)日:2006-06-06
  • US7285683B2
    申请人:——
    公开号:US7285683B2
    公开(公告)日:2007-10-23
查看更多